AU711832B2 - Endothelin antagonists - Google Patents

Endothelin antagonists Download PDF

Info

Publication number
AU711832B2
AU711832B2 AU32137/95A AU3213795A AU711832B2 AU 711832 B2 AU711832 B2 AU 711832B2 AU 32137/95 A AU32137/95 A AU 32137/95A AU 3213795 A AU3213795 A AU 3213795A AU 711832 B2 AU711832 B2 AU 711832B2
Authority
AU
Australia
Prior art keywords
trans
carboxylic acid
methoxyphenyl
benzodioxol
pyrrolidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU32137/95A
Other languages
English (en)
Other versions
AU3213795A (en
Inventor
Steven A. Boyd
Charles W Hutchins
Hwan-Soo Jae
Jeffrey A. Kester
Bryan K Sorensen
Andrew S. Tasker
Thomas W. Von Geldern
Martin Winn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Bahamas Ltd
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/442,575 external-priority patent/US5767144A/en
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of AU3213795A publication Critical patent/AU3213795A/en
Priority to AU20344/99A priority Critical patent/AU725122B2/en
Application granted granted Critical
Publication of AU711832B2 publication Critical patent/AU711832B2/en
Assigned to ABBVIE BAHAMAS LTD. reassignment ABBVIE BAHAMAS LTD. Alteration of Name(s) in Register under S187 Assignors: ABBOTT LABORATORIES
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/59—Hydrogenated pyridine rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Pyrrole Compounds (AREA)
AU32137/95A 1994-08-19 1995-08-04 Endothelin antagonists Expired AU711832B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU20344/99A AU725122B2 (en) 1994-08-19 1999-03-10 Endothelin antagonists

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US29334994A 1994-08-19 1994-08-19
US08/293349 1994-08-19
US33471794A 1994-11-04 1994-11-04
US08/334717 1994-11-04
US08/442575 1995-05-30
US08/442,575 US5767144A (en) 1994-08-19 1995-05-30 Endothelin antagonists
US49799895A 1995-08-02 1995-08-02
US08/497998 1995-08-02
PCT/US1995/009924 WO1996006095A1 (en) 1994-08-19 1995-08-04 Endothelin antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU20344/99A Division AU725122B2 (en) 1994-08-19 1999-03-10 Endothelin antagonists

Publications (2)

Publication Number Publication Date
AU3213795A AU3213795A (en) 1996-03-14
AU711832B2 true AU711832B2 (en) 1999-10-21

Family

ID=27501591

Family Applications (1)

Application Number Title Priority Date Filing Date
AU32137/95A Expired AU711832B2 (en) 1994-08-19 1995-08-04 Endothelin antagonists

Country Status (12)

Country Link
EP (2) EP1186603A3 (enExample)
JP (1) JP3741441B2 (enExample)
KR (2) KR100483222B1 (enExample)
AT (1) ATE219077T1 (enExample)
AU (1) AU711832B2 (enExample)
CA (2) CA2195677C (enExample)
DE (1) DE69527072T2 (enExample)
DK (1) DK0776324T3 (enExample)
ES (1) ES2179881T3 (enExample)
IL (2) IL114894A (enExample)
PT (1) PT776324E (enExample)
WO (1) WO1996006095A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5852046A (en) * 1993-08-03 1998-12-22 Hoechst Aktiengesellschaft Benzo-fused heterocyclic compounds having a 5-membered ring processes for their preparation their use as medicaments their use as diagnostic agents and medicaments containing them
US5767144A (en) * 1994-08-19 1998-06-16 Abbott Laboratories Endothelin antagonists
US6162927A (en) * 1994-08-19 2000-12-19 Abbott Laboratories Endothelin antagonists
US7208517B1 (en) 1994-08-19 2007-04-24 Abbott Labortories Endothelin antagonists
ES2259803T3 (es) * 1996-02-13 2006-10-16 Abbott Laboratories Nuevos derivados de pirrolidina sustituidos con benzo-1,3-dioxolilo y benzofuranilo como antagonistas de endostelina.
AU2763602A (en) * 1996-02-13 2002-05-16 Abbott Laboratories Endothelin antagonists
AU781355B2 (en) * 1996-02-13 2005-05-19 Abbott Laboratories Novel benzo-1,3-dioxolyl-and benzofuranyl substituted pyrrolidine derivatives as endothelin antagonists
PT888340E (pt) * 1996-02-13 2002-12-31 Abbott Lab Derivados de acido 4-(benzo-1,3-dioxolil)pirrolidino-3-carboxilico como antagonistas de endotelina
US5801250A (en) * 1996-12-13 1998-09-01 Abbott Laboratories Process for the stereoselective production of nitro-enamine compounds
US6030975A (en) * 1997-03-14 2000-02-29 Basf Aktiengesellschaft Carboxylic acid derivatives, their preparation and use in treating cancer
PL348667A1 (en) * 1997-06-17 2002-06-03 Abbott Lab Pyrrolidine carboxylic acid derivatives as endothelin antagonists
HUP0003484A3 (en) * 1997-08-04 2002-02-28 Abbott Lab Pyrrolidine-3-crboxylic acid derivatives and their use as endothelin antagonists
IL125658A0 (en) 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
US6339087B1 (en) 1997-08-18 2002-01-15 Syntex (U.S.A.) Llc Cyclic amine derivatives-CCR-3 receptor antagonists
DE19743681A1 (de) * 1997-10-02 1999-04-08 Knoll Ag Methode zur Verhinderung der Transplantatabstoßung
US6410554B1 (en) 1998-03-23 2002-06-25 Merck & Co., Inc. Combination therapy for the treatment of benign prostatic hyperplasia
NZ510145A (en) * 1998-09-14 2003-02-28 Warner Lambert Co Branched alkyl pyrrolidine-3-carboxylic acids useful in protective action against cardiazole cramp and cerebral conditions such as epilepsy, hypokinesia and cranial traumas
ATE386720T1 (de) 1998-11-20 2008-03-15 Hoffmann La Roche Piperidin ccr-3 rezeptor-hemmer
WO2002017912A1 (en) * 2000-08-31 2002-03-07 Abbott Laboratories Endothelin antagonists
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
RU2426532C2 (ru) 2004-03-17 2011-08-20 Новартис Аг Применение органических соединений
CA2697057A1 (en) 2007-08-22 2009-02-26 Gilead Colorado, Inc. Therapy for complications of diabetes
WO2011114103A1 (en) 2010-03-18 2011-09-22 Biolipox Ab Pyrimidinones for use as medicaments
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
MX352672B (es) 2011-09-27 2017-12-04 Amgen Inc Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer.
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
WO2014134201A1 (en) 2013-02-28 2014-09-04 Amgen Inc. A benzoic acid derivative mdm2 inhibitor for the treatment of cancer
WO2014151863A1 (en) 2013-03-14 2014-09-25 Amgen Inc. Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer
MA53572A1 (fr) 2013-06-10 2021-10-29 Amgen Inc Procédés de production et formes cristallines d'un inhibiteur mdm2
US8962675B1 (en) * 2013-09-12 2015-02-24 Abbvie Inc. Atrasentan mandelate salts
KR102091932B1 (ko) 2018-08-16 2020-03-20 장남순 안전하고 간편한 접첩구조를 갖는 접이식 트램펄린
CN120919117B (zh) * 2025-09-24 2026-06-09 中山大学 一种四取代吡咯衍生物在制备治疗神经退行性疾病的产品中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3342833A (en) * 1964-08-07 1967-09-19 Shell Oil Co Pyrrolidine production from aziridines and olefins

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI942059L (fi) * 1991-11-05 1994-07-04 Smithkline Beecham Corp Endoteliinireseptoreiden antagonisteja
JPH07509465A (ja) * 1992-07-17 1995-10-19 スミスクライン・ビーチャム・コーポレイション エンドセリン受容体アンタゴニスト

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3342833A (en) * 1964-08-07 1967-09-19 Shell Oil Co Pyrrolidine production from aziridines and olefins

Also Published As

Publication number Publication date
KR100447000B1 (ko) 2004-12-10
PT776324E (pt) 2002-11-29
HK1008328A1 (en) 1999-05-07
CA2517691A1 (en) 1996-02-29
AU3213795A (en) 1996-03-14
IL134905A (en) 2009-06-15
CA2195677A1 (en) 1996-02-29
IL114894A (en) 2003-04-10
KR20040045036A (ko) 2004-05-31
KR100483222B1 (ko) 2005-04-15
DE69527072T2 (de) 2003-02-13
KR970705561A (ko) 1997-10-09
WO1996006095A1 (en) 1996-02-29
DK0776324T3 (da) 2002-10-07
CA2195677C (en) 2005-11-08
EP1186603A3 (en) 2003-07-09
EP1186603A2 (en) 2002-03-13
IL114894A0 (en) 1995-12-08
IL134905A0 (en) 2001-05-20
DE69527072D1 (de) 2002-07-18
JPH10504565A (ja) 1998-05-06
EP0776324A1 (en) 1997-06-04
EP0776324B1 (en) 2002-06-12
JP3741441B2 (ja) 2006-02-01
ATE219077T1 (de) 2002-06-15
ES2179881T3 (es) 2003-02-01

Similar Documents

Publication Publication Date Title
EP0776324B1 (en) Endothelin antagonists
US6462194B1 (en) Endothelin antagonists
KR100508200B1 (ko) 엔도텔린길항제로서의벤조-1,3-디옥솔릴-및벤조푸라닐치환된피롤리딘유도체및이를함유하는약제
US6946481B1 (en) Endothelin antagonists
AU8592198A (en) Endothelin antagonists
WO2002017912A1 (en) Endothelin antagonists
AU714597B2 (en) 4-(benzo-1,3-dioxolyl)-pyrrolidine-3-carboxylic acid derivatives as endothelin antagonists
US7365093B2 (en) Endothelin antagonists
AU7826398A (en) Pyrrolidine carboxylic acid derivatives as endothelin antagonists
AU725122B2 (en) Endothelin antagonists
AU781355B2 (en) Novel benzo-1,3-dioxolyl-and benzofuranyl substituted pyrrolidine derivatives as endothelin antagonists
AU2005201160B2 (en) Endothelin antagonists
AU2008201198A1 (en) Endothelin anatagonists
NZ514170A (en) Benzo-1, 3-dioxolyl- and benzofuranyl substituted pyrrolidine derivatives as endothelin antagonists
CZ2000348A3 (cs) Deriváty pyrrolidin-3-karboxylové kyseliny a jejich použití jako antagonistů endothelinu
HK1008328B (en) Endothelin antagonists
NZ514171A (en) Benzo-1,3-dioxolyl- and benzofuranyl substituted pyrrolidine derivatives as endothelin antagonists

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 13, NO 38, PAGE(S) 5829 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAME ABBOTT LABORATORIES, SERIAL NO. 711832, INID (32), THE PRIORITY DATE OF 08/442575 SHOULD READ 30.05.95.